Literature DB >> 12931551

Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms.

Oscar Lin1, Semra Olgac, Ileana Green, Maureen F Zakowski, David S Klimstra.   

Abstract

Neuroendocrine neoplasms (NENs) of the lung and gastrointestinal tract constitute a pathologic and biologic spectrum of tumors. Accurate cytologic diagnosis of a neuroendocrine neoplasm is important since definitive treatment frequently is based on low- and high-grade categories without histologic sampling. In many instances, however, low- and high-grade NENs share cytologic features, hindering a precise classification. Since the histologic diagnostic criteria for separation of low- from high-grade categories can be based on the proliferation rate, we proposed to evaluate the usefulness of the immunocytochemical stain for the proliferation marker MIB-1 in the grading of NENs. Cytologic preparations of 63 NENs were retrieved from the files of Memorial Sloan-Kettering Cancer Center, New York, NY. One representative alcohol-fixed slide from each case was destained and restained immunocytochemically for MIB-1. When MIB-1 immunoreactivity was considered, all low-grade NENs showed immunoreactivity in fewer than 25% of the neoplastic cells, and all high-grade NENs demonstrated immunoreactivity in more than 50% of neoplastic cells. Our study demonstrates that MIB-1 dramatically stratifies NENs as low-grade or high-grade. Therefore, the proliferation index also correlates with grade of NEN in cytology specimens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12931551     DOI: 10.1309/TGCD-66L3-1DHY-X5HK

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  9 in total

1.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

2.  Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms.

Authors:  Carlie S Sigel; Huimin Guo; Keith M Sigel; Ming Zhang; Natasha Rekhtman; Oscar Lin; David S Klimstra; Achim A Jungbluth; Laura K Tang
Journal:  Cancer Cytopathol       Date:  2017-01-17       Impact factor: 5.284

Review 3.  Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.

Authors:  Silvia Uccella; Stefano La Rosa; Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

4.  Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied.

Authors:  Alessandra Fabbri; Mara Cossa; Angelica Sonzogni; Mauro Papotti; Luisella Righi; Gaia Gatti; Patrick Maisonneuve; Barbara Valeri; Ugo Pastorino; Giuseppe Pelosi
Journal:  Virchows Arch       Date:  2017-01-04       Impact factor: 4.064

5.  Diagnostic and prognostic implications of the World Health Organization classification of neuroendocrine tumors.

Authors:  A Faggiano; G Mansueto; P Ferolla; F Milone; M L del Basso de Caro; G Lombardi; A Colao; G De Rosa
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

6.  Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.

Authors:  Sandy Z Liu; Paul N Staats; Lindsay Goicochea; Borislav A Alexiev; Nirav Shah; Renee Dixon; Allen P Burke
Journal:  Diagn Pathol       Date:  2014-10-16       Impact factor: 2.644

Review 7.  Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis.

Authors:  Marina K Baine; Natasha Rekhtman
Journal:  Transl Lung Cancer Res       Date:  2020-06

8.  Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices.

Authors:  Natasha Rekhtman; Patrice Desmeules; Anna M Litvak; Maria C Pietanza; Maria Lauren Santos-Zabala; Ai Ni; Joseph Montecalvo; Jason C Chang; Amanda Beras; Isabel R Preeshagul; Joshua K Sabari; Charles M Rudin; Marc Ladanyi; David S Klimstra; William D Travis; Wei-Chu Lai
Journal:  Mod Pathol       Date:  2019-03-28       Impact factor: 7.842

9.  Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.

Authors:  Elizabeth Dudnik; Samuel Kareff; Mor Moskovitz; Chul Kim; Stephen V Liu; Anastasiya Lobachov; Teodor Gottfried; Damien Urban; Alona Zer; Ofer Rotem; Amir Onn; Mira Wollner; Jair Bar
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.